ISTH Congress Abstracts

Official abstracts site for the ISTH Congress

MENU 
  • Home
  • Congress Archive
    • ISTH 2020 Congress
  • Resources
  • Search

Non-Sever Hemophilia Is Not Benign? – Insights from the PROBE Study

C. Chai-Adisaksopha1, R. Curtis2, N. Frick3, M. Nichol4, D. Noone5, F. Germini6, B. O'Mahony5, D. Page7, J. Stonebraker8, M. Skinner6,9, A. Iorio10,11, PROBE

1Chiang Mai University, Internal Medicine, Chiang Mai, Thailand, 2Factor VIII Computing, Berleley, United States, 3National Hemophilia Foundation, New York, United States, 4University of Southern California, Sol Price School of Public Policy, Los Angelis, United States, 5Irish Haemophilia Society, Dublin, Ireland, 6McMaster University, Hamilton, Canada, 7Canadian Hemophilia Society, Montreal, Canada, 8North Carolina State University, Poole College of Management, Raleigh, United States, 9Institute for Policy Development Ltd, Washington, United States, 10McMaster University, McMaster-Bayer Endowed Research Chair in Clinical Epidemiology of Congenital Bleeding Disorders, Hamilton, Canada, 11McMaster University, Department of Health Research Methods, Evidence, and Impact, Hamilton, Canada

Abstract Number: PB1005

Meeting: ISTH 2020 Congress

Theme: Hemophilia and Rare Bleeding Disorders » Hemophilia - Clinical

Background: There are limited data on the impact of haemophilia on health status and health-related quality of life (HRQL) in people affected by non-severe haemophilia.

Aims: To evaluate the health status of people living with mild or moderate haemophilia.

Methods: A cross-sectional, multinational study was conducted as part of the Patient Reported Outcomes, Burdens and Experiences (PROBE) project. Respondents without bleeding disorder (NoBD) and those with mild or moderate haemophilia were included. Respondents were asked to complete the PROBE questionnaire, which contains haemophilia-related questions, general health questions and HRQL. Results were compared between unaffected individuals and people with mild or moderate haemophilia.

Results: A total of 862 respondents, of whom 144 with moderate haemophilia, 143 with mild haemophilia and 575 with NoBD were included. Median age (first-third quartile) was 33 (23-46),42 (25-55) and 43 (35-54), respectively. In relation to bleeding in the previous 12 months, respondents with mild reported less bleeding frequency than those with moderate haemophilia, with similar patterns of bleeding frequency seen in both male and female cohorts. Reporting of acute pain is less in those with NoBD compared to the mild to moderate cohorts for both genders (male – 33%, 67%, 77%; female 38%,52%, 67%, respectively). Thirteen percent of those with NoBD reported an impact on activities of daily living compared with mild and moderate haemophilia who reported of 35% and 61%, respectively. The impact on quality of life due to mild haemophilia compared to those with NoBD was a reduction of 5.2%, 5.0% and 9.3% in VAS, EQ-5D-5L and PROBE Score respectively (p≤0.001).

Conclusions: People affected by mild or moderate hemophilia encountered a significant amount of haemophilia related sequalae. Future research is needed to identify the optimal management of moderate and mild hemophilia patients, with particular focus on early identification of patients with a severe clinical phenotype.

To cite this abstract in AMA style:

Chai-Adisaksopha C, Curtis R, Frick N, Nichol M, Noone D, Germini F, O'Mahony B, Page D, Stonebraker J, Skinner M, Iorio A, PROBE . Non-Sever Hemophilia Is Not Benign? – Insights from the PROBE Study [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1). https://abstracts.isth.org/abstract/non-sever-hemophilia-is-not-benign-insights-from-the-probe-study/. Accessed April 16, 2021.
Save to PDF

« Back to ISTH 2020 Congress

ISTH Congress Abstracts - https://abstracts.isth.org/abstract/non-sever-hemophilia-is-not-benign-insights-from-the-probe-study/

Simple Search

ISTH 2020 Congress site

Visit the official web site for the ISTH 2020 Virtual Congress »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2021 John Wiley & Sons, Inc. All Rights Reserved.
Wiley
This site uses cookies: Find out more.